(Total Views: 988)
Posted On: 12/04/2023 11:20:32 AM
Post# of 148878
HIV, immune senescence, immune dysregulation and aging.
“the availability of long-term viral suppression treatment has not been successful in normalizing elevated markers of systemic immune activation”
https://www.mdpi.com/2227-9059/11/1/159
With the recent much discussed peek behind the curtain regarding a prospective HIV trial of Leronlimab suggested by the key opinion leaders which were convened and by all appearances the FDA seems inclined to agree, while some may view this as tweaking the goal posts I see the trial, forged with proper endpoints well established with CCR5 inhibition, as both highly likely to succeed and with the power to shift the spotlight on leronlimab away from viral suppression and towards immune modulation. While Big Pharma may be more interested in a longer acting drug q month or q 3 months, the reality is Leronlimab is a subq injection much like insulin that patients get used to and because it should conquer both twin towers: viral suppression and the immune dysregulation behind the increased morbidity and eventual mortality, it should rightly become standard of care and supplant much of the existing anti-retroviral therapies. While that would be very market moving, the accent on immune modulatory function will kick the door wide open to a whole host of diseases and syndromes crystallized by OHM’s list of prospective indications based on mechanism of action.
While this has already captured the attention of the longs on this board, it should also capture the attention of the FDA, Big Pharma, and by extension Wall Street.
We should look ahead, not behind; if the trial is well conceived with end points that Jay Lalezari is fully aware support WHAT WE HAVE ALREADY SEEN in clinical trials, the best days are ahead both for us as well as patients.
“the availability of long-term viral suppression treatment has not been successful in normalizing elevated markers of systemic immune activation”
https://www.mdpi.com/2227-9059/11/1/159
With the recent much discussed peek behind the curtain regarding a prospective HIV trial of Leronlimab suggested by the key opinion leaders which were convened and by all appearances the FDA seems inclined to agree, while some may view this as tweaking the goal posts I see the trial, forged with proper endpoints well established with CCR5 inhibition, as both highly likely to succeed and with the power to shift the spotlight on leronlimab away from viral suppression and towards immune modulation. While Big Pharma may be more interested in a longer acting drug q month or q 3 months, the reality is Leronlimab is a subq injection much like insulin that patients get used to and because it should conquer both twin towers: viral suppression and the immune dysregulation behind the increased morbidity and eventual mortality, it should rightly become standard of care and supplant much of the existing anti-retroviral therapies. While that would be very market moving, the accent on immune modulatory function will kick the door wide open to a whole host of diseases and syndromes crystallized by OHM’s list of prospective indications based on mechanism of action.
While this has already captured the attention of the longs on this board, it should also capture the attention of the FDA, Big Pharma, and by extension Wall Street.
We should look ahead, not behind; if the trial is well conceived with end points that Jay Lalezari is fully aware support WHAT WE HAVE ALREADY SEEN in clinical trials, the best days are ahead both for us as well as patients.
(21)
(0)Scroll down for more posts ▼
